Brought to you by 
Theravance grants SciClone certain Asian rights to Vibativ
23 Jul 2019
Executive Summary
SciClone Pharmaceuticals Inc. received exclusive rights to develop and commercialize Theravance Biopharma Inc.'s Vibativ (telavancin) antibiotic in China, Hong Kong, Macau, Taiwan, and Vietnam.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Theravance grants SciClone certain Asian rights to Vibativ
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice